NVAX

Novavax develops vaccine candidates using protein-based technology platforms, including proprietary adjuvants (Matrix-M, Matrix-A, Matrix-C, Matrix-V), with a marketed COVID-19 vaccine (Nuvaxovid) and additional vaccine candidates in development. The company has a history of operating losses and depends on collaboration agreements, funding arrangements, and advance purchase agreements to support ongoing operations and vaccine development. Novavax faces typical biotech risks including uncertain clinical development timelines, dependence on new technologies, and the need for continued significant funding.

Pipeline

Catalyst Calendar